Solana Company (HSDT) Q1 2026 Earnings Call Transcript
Solana Company Reports First Quarter 2026 Financial Results
Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026
Jito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific Region
Solana Company (NASDAQ: HSDT) Announces Registered Direct Offering of Common Stock to Global Institutional Investor
Comparing Solana (NASDAQ:HSDT) and Covalon Technologies (OTCMKTS:CVALF)
Solana Company: A Compelling NAV Play
Solana Company (NASDAQ: HSDT) Appoints Madelene Gani as Chief Operating Officer and Deputy CFO to Lead Next Phase of Growth
Solana Company (HSDT) Q4 2025 Earnings Call Transcript
Solana Company Reports Fourth Quarter and Full Year 2025 Financial Results
Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026
Solana (HSDT) to Release Earnings on Tuesday
Solana Company (NASDAQ: HSDT) Becomes First Digital Asset Treasury to Enable Borrowing Against Natively Staked SOL in Qualified Custody
Solana Company (HSDT) Q3 2025 Earnings Call Transcript
Solana Company Reports Third Quarter 2025 Financial Results
Solana Company to Release Third Quarter Operating Results on November 18, 2025
CORRECTION – Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield
Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services
Solana Company Executive Chairman's Message: October 20th, 2025
Solana Company (NASDAQ:HSDT) Selects BitGo as Custodian for SOL Treasury Holdings
Preeminent SOL Treasury Vehicle, Solana Company (NASDAQ:HSDT), Adds Coinbase, BitGo, and Anchorage Digital as Custodians
Preeminent SOL Treasury Company Helius (NASDAQ:HSDT) Announces Corporate Name Change to Solana Company and Letter of Intent with Solana Foundation
Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke
Helius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain
Helius (NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital Closes Over $500 Million Private Placement to Launch SOL Treasury Company
Helius (NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital Announces Over $500 Million in Funding to Launch SOL Treasury Company
Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
Helius Medical Technologies, Inc. Compliant with Nasdaq's Continued Listing Requirements
Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Helius Medical Technologies Announces Reverse Stock Split
Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting
Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
Helius Medical Technologies Announces Reverse Stock Split
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market
Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript